GURUFOCUS.COM » STOCK LIST » Financial Services » Credit Services » Ventana Biotech Inc (OTCPK:VNTA) » Definitions » Accounts Receivable

VNTA (Ventana Biotech) Accounts Receivable : $0.00 Mil (As of . 20)


View and export this data going back to 2008. Start your Free Trial

What is Ventana Biotech Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Ventana Biotech's accounts receivables for the quarter that ended in . 20 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Ventana Biotech's Net-Net Working Capital per share for the quarter that ended in . 20 was $N/A.


Ventana Biotech Accounts Receivable Historical Data

The historical data trend for Ventana Biotech's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ventana Biotech Accounts Receivable Chart

Ventana Biotech Annual Data
Trend
Accounts Receivable

Ventana Biotech Semi-Annual Data
Accounts Receivable

Ventana Biotech Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Ventana Biotech Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Ventana Biotech's Days Sales Outstanding for the quarter that ended in . 20 is calculated as:

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Ventana Biotech's accounts receivable are only considered to be worth 75% of book value:

Ventana Biotech's Net-Net Working Capital Per Share for the quarter that ended in . 20 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(+0.75 * +0.5 * -N/A
--)/0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Ventana Biotech Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Ventana Biotech's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Ventana Biotech Business Description

Traded in Other Exchanges
N/A
Address
1660 South Albion Street, Suite 1007, Denver, CO, USA, 80222
Ventana Biotech Inc is a development stage company providing alternative financing in the capacity of a broker for those commercial borrowers in need of non-bank financing.